Advanced Filters
noise

Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,190 clinical trials

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and …

18 years of age All Phase 3
A Ana Ayala

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

18 years of age All Phase 1
T Tan Jie

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

18 - 70 years of age All Phase N/A
V Victoria E. Cosgrove, PhD

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.

8 - 18 years of age All Phase N/A

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm …

18 - 120 years of age All Phase 1/2
A Andrew Hantel, MD

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

18 years of age All Phase N/A
D Dimpy Modi

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates …

18 years of age All Phase N/A
C Caner Saygin, MD

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute …

18 years of age All Phase 1/2
M Michelle Fujimoto

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults …

1 - 25 years of age All Phase 1
F Fatma Ebeid

Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia

This current study will implement a proposed whole program of monitoring and prevention acute hepatic injury during the time of induction chemotherapy in children and adolescent with ALL.

2 - 18 years of age All Phase 4

Simplify language using AI